Care about patients with chronic rhinosinusitis and type-2 inflammation

In the last 20 years, growing interest towards rhinosinusitis became evident in medical literature; yet, it is still difficult to identify the real prevalence of chronic rhinosinusitis (CRS). Epidemiological studies are few and they are built on heterogeneous populations and diagnostic methods. The major step forward has been an increasing awareness of CRS as a disease characterized by heterogeneous clinical scenarios, high impact on quality of life and elevated social costs. Patient stratification in phenotypes, identification of the pathobiological mechanism at the origin of the disease (endotype) and its comorbidities, are pivotal in the diagnostic process and they should be addressed to tailor the treatment. A multidisciplinary approach and shared diagnostic-therapeutic processes are therefore mandatory. Oncological multidisciplinary boards are models to imitate. The role of a multidisciplinary board is inspired to precision medicine principles: tracing a diagnostic pathway with the purpose of identifying the patient’s immunological profile, monitoring therapeutical processes, abstaining from the selfish experience of a single specialist, and placing the patient at the center of the therapeutic plan. Patient participation is a fundamental step to optimize the disease clinical course, improving patient’s quality of life and reducing the socioeconomical burden.MAIN TEXT